Alloksys Life Sciences BV Obtains 3.4 million EURO Innovation Credit

Alloksys Life Sciences BV, a biopharma SME based in The Netherlands, has been granted an Innovation Cedit (’Innovatiekrediet’) of 3.4 million EUR by the Netherlands Enterprise Agency for the execution of Phase 3 clinical trials leading to registration of RESCAP® (RESCuing Alkaline Phosphatase*) for the prevention and treatment of ischemic injury and inflammation mediated complications in cardiothoracic surgery (APPIRED III).

ICM Pharma invests €5.25 million in Alloksys Life Sciences to support Phase 3 clinical study trials of RESCAP® drug

Dutch based Alloksys Life Sciences BV has signed and closed agreements with the fastest growing local pharmaceutical company in Singapore, ICM Pharma,Pte. Ltd. to invest €5.25 million (approximately S$8.1 million) for a minority stake in Alloksys and an exclusive license to market and produce RESCAP® (RESCuing Alkaline Phosphatase*) for prevention and treatment of ischemic injury and inflammation mediated complications in cardiothoracic surgery in Asia.